
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded topical gel containing methotrexate, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing methotrexate are listed in oral solution, tablet and injection forms. No finished methotrexate product of any kind is listed in gel form.
Gel bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Methotrexate is a folate antagonist for certain cancers and autoimmune conditions, taken by mouth or injected, that a pharmacy may compound on a prescriber's order.
Methotrexate is an antimetabolite that blocks dihydrofolate reductase, the enzyme that activates folic acid. Without active folate, cells cannot make the building blocks of DNA, so fast-dividing cells are affected most; the label states that its mechanism in rheumatoid arthritis and psoriasis is unknown, and StatPearls describes additional anti-inflammatory effects. Manufactured products include generic methotrexate tablets and Trexall tablets, Xatmep and Jylamvo oral solutions, methotrexate injection, and Otrexup and Rasuvo autoinjectors. Methotrexate tablets are labeled for acute lymphoblastic leukemia, mycosis fungoides and relapsed or refractory non-Hodgkin lymphomas, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe psoriasis; injection products carry additional cancer indications. A prescriber might order methotrexate compounded in a strength or form that is not manufactured, or without a particular dye or excipient. Compounded preparations are not FDA-approved and require a prescription.
Methotrexate labels carry a boxed warning: it can cause embryo-fetal toxicity, including fetal death, and is contraindicated in pregnancy for non-cancer conditions; it is contraindicated after a severe allergic reaction to methotrexate; serious reactions, including death, can affect the bone marrow, gut, liver, lungs, skin and kidneys; and taking a weekly dose daily by mistake has caused deaths. Other warnings include serious infections, nerve toxicity, secondary cancers, sun sensitivity, infertility and avoiding live vaccines. Use reliable birth control during treatment and for 6 months after the last dose (3 months for males with female partners who could become pregnant). NSAIDs including aspirin, proton pump inhibitors, penicillins, sulfonamides, probenecid, other antifolates such as dapsone, and nitrous oxide anesthesia can raise toxicity. Heavy alcohol use raises liver risk. The label says not to breastfeed during treatment and for 1 week after; LactMed notes that some guidelines accept low weekly doses during breastfeeding. Talk to your prescriber or pharmacist about side effects.
Methotrexate inhibits dihydrofolate reductase, interfering with purine and thymidylate synthesis; it forms active polyglutamates that persist in tissues, and StatPearls describes AICAR transformylase inhibition and adenosine-mediated anti-inflammatory effects. Per the Teva tablet label, oral bioavailability is about 60% at lower doses, with peak levels at 0.75 to 6 hours; food delays absorption; it is about 50% protein bound, does not penetrate the CSF at recommended oral doses, has an elimination half-life of about 3 to 10 hours, and is cleared mainly by the kidneys. It accumulates in third spaces such as pleural effusions and ascites. Labeled indications (methotrexate tablets, ANDA): ALL maintenance, mycosis fungoides, relapsed or refractory non-Hodgkin lymphoma, rheumatoid arthritis, pJIA and severe psoriasis. StatPearls lists dermatomyositis, pityriasis rubra pilaris, eczema, sarcoidosis and ANCA-associated vasculitis as off-label uses; these are not FDA-approved indications. Verify pregnancy status before starting. Monitor blood counts, liver tests and renal function at baseline and periodically, and watch for pulmonary, dermatologic and neurologic toxicity. Give folic or folinic acid in non-neoplastic disease per the label. Glucarpidase is labeled for toxic levels with delayed clearance from renal impairment. Methotrexate is not a controlled substance. Dosing is per prescriber, with weekly regimens clearly labeled.
Wash your hands. Apply the amount on your label to clean, dry skin and spread it in a thin layer. For a metered pump, your label states the number of presses. For a dosing syringe, push the plunger to the mark. Let the gel dry before covering with clothing. Wash your hands afterward and keep the site from touching other people until it has dried. Do not apply to broken skin unless told to.
A gel can have a nonaqueous or a water-based base, and USP <795> sets its default beyond-use date by water content, not by the word gel. A nonaqueous gel usually carries a beyond-use date of up to 180 days at room temperature or refrigerated. A water-based gel carries up to 35 days with a preservative, or 14 days refrigerated without one. Your label states which applies. Keep the container closed, away from heat and open flame if it contains alcohol, out of reach of children, and discard after the beyond-use date on your label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Apply topically to affected area(s)